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Background: Esophageal cancer (EC) is one of the most common cancers worldwide. The cancer-related inflammation
pathway- signal transducer and activator of transition 3 (STAT3) signaling pathway has been reported to play critical role
in its initiation and progression, while the way mediated its hyperactivation remains elusive so far. Accumulating studies
reported the important role of microRNAs (miRNAs) in the regulation of gene expression, among of which, the miR-124/
STAT3 interaction has been widely reported in various cancers, while its role in EC has not been investigated yet.
Methods: Firstly, we identified the target role of STAT3 in esophageal cancers using Dual-luciferase reporter assays. Next,
we explored the expression of miR-124 in EC tissues. To further investigate its effects on the malignant phenotype of EC
cells, we completed a series of experiments. Through transfection with miR-124 mimic, the expression of miR-124
in esophageal cancer cell lines, Eca109 and TE-1, were restored. Next, we detected the effects of ectopic miR-124
expression on the proliferation, cell cycle distribution, apoptosis, migration and invasion of EC cells in vitro, and
the tumor growth in vivo.
Results: Dual-luciferase assays identified that STAT3 is a target gene of miR-124 in esophageal cancer cells.
Over-expression of miR-124 significantly down-regulated the mRNA and protein levels of STAT3. Moreover, we
found that the expression of miR-124 was consistently suppressed in esophageal cancer tissues and cell lines.
Next, functional experiments showed that ectopic expression of miR-124 in EC cells induced a complex phenotype,
namely an inhibition of cell proliferation, block of G1/S phase transition, induction of cell apoptosis, and suppression of
cell invasion in vitro, as well as inhibition of tumor growth in vivo. Moreover, restored the expression of STAT3
in esophageal cancer cells transfected with miR-124 before, could partially abolished the suppressive effects of
miR-124 on the proliferation and invasion of Eca109 cells.
Conclusion: Collectively, these data suggest that miR-124 functions as a tumor suppressor in esophageal cancer
through, at least partially, targeting STAT3 signaling pathway.
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Esophageal cancer is one of the most common cancers
worldwide, which is ranked eighth in incidence and sixth
in mortality [1]. Since the 1990s, its morbidity and mor-
tality among the world rose steadily, especially in the
rural areas. The etiology of this neoplasm is complex. In
addition to the genetic and environmental factors, diet
and lifestyle also contribute to the complicate scenario,* Correspondence: liyang_sam@163.com
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standard prevention and chemotherapy regimen [2].
Thus, a comprehensive understanding of the biology
about this malignancy is definitely necessary to the de-
velopment of novel therapies.
Currently, the role of chronic inflammation in the
esophageal carcinogenesis has been widely explored
[3]. A key concept of the cancer-related inflammation
pathway is that some genetic events endow cancer
cells with growth advantages [4], among of which, an
important one is the signal transducer and activator of
transcription-3 (STAT3) signaling pathway [5]. STAT3
is a critical member of the STAT transcription factor family.rticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
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formation, translocation to the nucleus, recognition of
STAT3-specific DNA-binding elements, and transcrip-
tional activation of the target genes [6]. Thus, by targeting
various genes STAT3 has been reported to participate in a
variety of physiological progresses, such as cell prolifera-
tion, apoptosis and so on [7,8]. For esophageal cancer,
STAT3 was constitutively activated in cancer tissues [9],
and overexpression of STAT3 could activate esophageal
epithelium cells to form tumors in vivo by up-regulating
Oct-1 [10]. Otherwise, its suppression was also investi-
gated to be involved in metformin-mediated autophagy
and apoptosis promotion of esophageal squamous cell car-
cinoma [11]. In view of the critical role of STAT3 in
esophageal carcinogenesis, the way mediated its hyperacti-
vation remains elusive so far.
Nowadays, accumulating studies reported the important
role of microRNAs (miRNAs) in the regulation of gene ex-
pression. MiRNAs represent a group of endogenous, small,
non-coding RNAs [12], which induce various target genes
translational silence or cleavage by partially complementing
with the 3’-untranslated region (3’UTR) of specific messen-
ger RNAs [13]. The interplay between miRNAs and STAT3
signaling pathway has been widely studied [14]. Among of
these miRNAs, miR-124, which is a kind of highly con-
served miRNA, attracted our attention. In addition to regu-
lating nervous system development [15], it also acts as a
tumor suppressor, as well as an independent prognostic
marker for many kinds of cancers [16,17]. STAT3 has been
reported to be the target gene of miR-124 in endometrial
cancer cells, and be involved in the miR-124-mediated sup-
pressive effects on endometrial cancer cells [18]. Strikingly,
rs531564 GG polymorphism of primary gene of miR-124,
pri-miR-124-1 which may promote the expression of miR-
124, has been observed to show significant effects on de-
creasing the risks of esophageal squamous cell carcinoma
in subgroups of elderly persons, females, no drinking and
no smoking Chinese people [19]. These make us speculate
that miR-124 might function as a potential tumor suppres-
sor in esophageal caner, and STAT3 signaling pathway
might be involved in the suppressive effects.
Thus, in this study, we firstly explored the expression
of miR-124 in 67 paired esophageal cancer tissues, and
then investigated its effects on the malignant phenotype
of esophageal cancer cells. Then, we further explored
whether the effects of miR-124 on cell proliferation and
invasion are mediated by STAT3.
Methods
Tissue specimens
67 formalin fixed paraffin-embedded specimens of esopha-
geal cancer tissues were collected from department of Di-
gestive Diseases, the Second Affiliated Hospital of Medical
School of Xi’an Jiaotong University. The matched normaltissues were obtained from the 5 cm distant from the
tumor margin, which were further confirmed by patholo-
gists. All patients did not perform any therapy before re-
cruitment to this research. The use of the tissue samples
for all experiments were obtained with informed consent
and approved by the Second Affiliated Hospital of Medical
School of Xi’an Jiaotong University institutional Ethics
Committee.
Cell culture and transfection
Human normal esophageal cell line Het-1A and three hu-
man esophageal cancer cell lines (Eca109, Ec9706 and
TE-1) were obtained from the American Type Culture
Collection (ATCC, Manassas, VA, USA). These cells were
maintained in Dualbecco’s modified Eagle’s medium
(DMEM, Invitrogen, CA, USA) supplemented with 10%
fetal bovine serum (FBS; PAA, Pasching, Austria) and
streptomycin (100 μg/mL), penicillin (100 U/mL). Cultures
were incubated in a humidified atmosphere of 5% CO2 at
37°C. Transfection of oligonucleotides were performed as
previously supplemented [20]. MiR-124 and relative scram-
ble mimic were purchased from Dharmacon (Austin, TX,
USA). According to manufacturer’s instructions, all oligo-
nucleotides were transfected into ECa109 and TE-1 cells to
a final concentration of 50 nM by Dhamafect 1 (Dharma-
con, Lafayette, CO, USA). Cells were collected for further
experiments 48 h post-transfection.
RNA extraction, reverse transcription and quantitative
real-time PCR
According to the protocol of Recover All Total Nucleic
Acid Isolation Kit (Ambion, Austin, TX, USA), total
RNA was isolated from 20-μm sections from formalin-
fixed, paraffin-embedded tissue blocks. The expression
level of U6 and GAPDH was regard as an internal con-
trol of miRNAs and mRNA, respectively. Total RNA
was reversely transcribed using First-Strand cDNA Syn-
thesis kit (Invitrogen, Carlsbad, CA, USA) with specific
primers qualified with a Taqman probe. Then, quantita-
tive real-time PCR was performed to quantify relative
expression of miRNA and mRNA using the Quanti-
TectSYBR Green PCR mixture on an ABI PRISM 7900
Sequence Detection System (Applied Biosystems, Carls-
bad, CA, USA). The primers used for reverse transcrip-
tions and quantitative RT-PCR were summarized in
Table 1. The relative expression levels were evaluated
using the 2-△△Ct method.
Plasmid construction and luciferase reporter assays
The Eca109 and TE-1 cells were seeded in triplicate in
24-well plates and allowed to settle for 12 h. The whole 3’-
UTR of STAT3 gene was cloned and amplified. Mutation
in 3’-UTR of STAT3 gene with miR-124 putative target
binding site deleted was generated with the QuickChange

























F for forward, R for reverse.
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the wild and mutant STAT3 genes were cloned into the
pGL-3-vector (Promega, Wisconsin, USA) immediately
downstream of the Renilla luciferase gene. A luciferase re-
porter construct containing the miR-124 consensus tar-
get sequence served as the positive control (PC) and
the pRL-TK vector was used as positive and internal
controls (PC), respectively. Cells were co-transfected
with pGL-3 firefly luciferase reporter (50 ng), pRL-TK
Renilla luciferase reporter (10 ng) and miR-124 (50nM)
or scramble mimic (50nM) with Lipofectamine 2000
(Invitrogen, Carlsbad, CA, USA). Cell lysates were pre-
pared using Passive Lysis Buffer (Promega, Wisconsin,
USA) 48 h upon transfection, and luciferase activity was
measured using the Dual-Luciferase Reporter Assay (Pro-
mega, Wisconsin, USA). Results were normalized to the
Renilla luciferase.
CCK-8 assays
The Cell Counting Kit-8 (CCK-8, Dojindo, Kumamoto,
Japan) Assays were performed to explore the effects of
miR-124 on the proliferation of Eca109 and TE-1 cells.
5 × 103 cells were plated into 24-well plates upon trans-
fection with miR-124 mimic. The CCK-8 reagents were
added to the each wells at 0 h, 24 h, 48 h, and 72 h post-transfection, and cells were diluted in normal culture
medium at 37°C until visual color conversion occurred.
The absorbance values in each well were measured with
a microplate reader set at 450 nm and 630 nm.
FACS analysis
For analysis of cell apoptosis, Eca109 and TE-1 cells were
collected and diluted to a concentration of 1 × 106 cells/ml
and washed with ice-cold PBS three times 72 h after trans-
fection. Cells were incubated with PE Annexin-v and
7AAD according to the PE Annexin v Apoptosis Detec-
tion Kit I(BD Pharmingen, CA, USA) protocol. For ana-
lysis of cell cycle distribution, cells were harvested 48 h
upon transfection with miR-124 mimic. Cells were
washed twice with cold PBS, fixed in ice-cold 70% etha-
nol, and incubated with propidium iodide (PI) and
RNase A. Cells harvested in two experiments were all
analyzed by fluorescence-activated cell sorting (FACS).
Data were analyzed with Flowjo software.
Cell migration and invasion assays
Migration assays were carried out in modified Boyden
chambers (BD Biosciences, San Jose, CA, USA) with 8 μm
pore filter inserts in 24-well plates. 24 hours after transfec-
tion, 2 × 105 cells suspended in serum-free DMEM were
added to the upper chamber. While for invasion assays,
the transwell chambers were coated with Matrigel (BD
Biosciences, San Jose, CA, USA) before, and 4 × 105 cells
were added to the upper chamber after 24 h of transfec-
tion. DMEM containing 20% FBS were added to the lower
chambers as a chemoattractant. After 24 h incubation, the
non-filtered cells in both assays were gently removed with
cotton swabs. Filtered cells located on the lower side of
the chamber were stained with crystal violet, air dried and
photographed.
Immunoblot analysis
For the Immunoblot assays, cells were harvested in ice-
cold PBS 48 h after transfection and lysed on ice in cold
modified radioimmunoprecipitation buffer supplemented
with protease inhibitors. Upon protein concentration was
determined using the BCA Protein Assay Kit, equal
amounts of protein were analyzed by SDS-PAGE. Gels
were electroblotted onto nitrocellulose membranes
(Millipore, Wisconsin, USA). After blocked with 5% non-
fat dry milk in Tris-buffered saline containing 0.1%
Tween-20 2 h, membranes were incubated at 4°C over
night with primary antibodies (STAT3, p-STAT3, Bcl-xL,
MMP-9 and GAPDH, Cell Signaling, Massachusetts,
USA). Then, membranes were incubated with respective
second antibodies and detected by peroxidase-conjugated
secondary antibodies using the enhanced chemilumines-
cence system (ECL) (Millipore, Wisconsin, USA).
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Animal xenograft model studies were performed accord-
ing to institutional guidelines; 4 × 106 Eca-109 cells were
inoculated subcutaneously in posterior flanks of 6-week-
old female nude mice, four mice per group. When tu-
mors reached 100 mm3, miR-124 mimic and relative
scramble mimic diluted in lipofectamine 2000 solution
(100 nmol mimic in 100 μl total volume) were injected
directly into the tumors, respectively. The tumors were
injected every 4 days for a total of six times. Tumor di-
ameters were measured after 10 days from injection and
then every three days. After 28 days after injection, mice
were killed and tumors were weighted after necropsy.
Tumor volume was calculated as follows: length ×
width2 × 1/2. All animals received humane care in com-
pliance with the Public Health Service Policy on Hu-
mane Care and Use of Laboratory Animals. The use of
animals for all experiments were obtained with informed
consent and approved by the Second Affiliated Hospital
of Medical School of Xi’an Jiaotong University institu-
tional Ethics Committee.
Statistical analysis
Data were expressed as the mean ± standard deviation of
at least three independent experiments. Statistical ana-
lysis was carried out using the Student’s t-test for com-
parisons of two groups, unless otherwise indicated (χ2
test), and data with three groups were analyzed using a
one-way analysis of variance (ANOVA). Statistical analysisFigure 1 MiR-124 targets STAT3 gene in esophageal cancer cells. (A) Re
both esophageal cancer cell lines, co-transfected with miR-124 mimic or scram
detect the expression of STAT3 upon transfection with miR-124 mimic or scram
expression levels of STAT3, p-STAT3, Bcl-xL and MMP-9 proteins in esophageawas carried out using SPSS 15.0 software. P-values < 0.05
were considered significant.
Results
MiR-124 directly targets STAT3 in esophageal cancer cells
Although a previous work has reported that STAT3 sig-
naling pathway is involved in miR-124-mediated tumor
suppression on endometrial cancer cells, it remains open
whether or not STAT3 is also be its putative gene in
esophageal cancers. According to the putative binding site
of miR-124 in the 3’UTR of STAT3 gene previously re-
ported [18], luciferase reporter assays were performed.
Co-transfection with miR-124 and constructs containing
the 3’UTR of miR-124 putative binding site led to signifi-
cant suppression of luciferase activity in both esophageal
cancer cell lines (Figure 1A), suggesting that miR-124 sup-
pressed the transcription activity of STAT3 gene in
esophageal cancer cells by targeting the putative 3’UTR
of STAT3 mRNA independently. Identical to the lucif-
erase reporter assays, we observed the consistently de-
creased expression of mRNA and protein of STAT3
upon transfection with miR-124 mimic in both cell
lines (Figure 1B and C). Otherwise, since STAT3 has
been reported to participate in variety of biological pro-
gresses by targeting different down-stream genes, such
as Bcl-xL andMMP-9 [21-23], we also explored the effects
on the expression of these genes upon transfection. As ex-
pected, ectopic expression of miR-124 suppressed the
expression of phosphorylated STAT3 at tyrosine 705lative luciferase activity of the indicated STAT3 reporter construct in
ble mimic, is shown; (B) Quantitative RT-PCR assays were performed to
ble mimic (normalized to GAPDH); (C) Western blot analysis showed the
l cancer cells upon transfection with miR-124 mimic. **P < 0.01.
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MMP-9 protein at same time. Collectively, these findings
identified that miR-124 regulates the expression of STAT3
post-transcriptionally in esophageal cancer cells.
MiR-124 expression was consistently suppressed in
esophageal cancer tissues and cell lines
The fact that STAT3 signaling pathway has been widely re-
ported to be activated in esophageal cancer tissues, and
perform important function in the initiation and progres-
sion of this tumor make us to speculate that whether miR-
124 was involved in its regulation and function. In an
attempt to explore the expression and significance of miR-
124 in esophageal carcinogenesis, we firstly detected the
expression of miR-124 in 67 pairs of esophageal cancer tis-
sues and adjacent normal tissues (Table 2). As shown in
Figure 2A, relative to the adjacent normal tissues majority,
about 67% (45 out of 67), of selected esophageal cancer
tissues exhibited under-expression of miR-124. In order to
observe the tendency of miR-124 expression intuitively,
we further performed the statistical analysis the miR-124Table 2 Relationship between miR-124 expression and










<60 38 1.301 ± 0.8616 0.8220
≥60 29 1.344 ± 0.6687
Gender:
Male 52 1.267 ± 0.7489 0.3017
Female 15 1.504 ± 0.8765
Tumor size (cm):
≤4 45 1.344 ± 0.8002 0.7154
>4 22 1.270 ± 0.7485
Degree of differentiation:
Well and moderately 27 1.590 ± 0.8159 0.0182*
Poorly 40 1.137 ± 0.7052
Local invasion:
T1 + T2 24 1.604 ± 0.6710 0.0245*
T3 + T4 43 1.161 ± 0.7965
TNM stage:
StageI + II 42 1.434 ± 0.8117 0.1192
Stage III + IV 25 1.127 ± 0.6930
Metastasis:
No 41 1.362 ± 0.7076 0.5831
Yes 26 1.253 ± 0.8900
P-value represents the probability from a Student’s t-test for miR-124 expression
between variable subgroups. *P < 0.05 was considered to have a significant
difference.expression, which indicated that the expression of miR-
124 is much lower in cancer tissues compared with the
normal tissues (Figure 2B). The generality of this observa-
tion was further confirmed in esophageal cancer cell lines.
Comparing with the human normal esophageal cell line
Het-1A, the expression of miR-124 is consistently down-
regulated in three different esophageal cancer cell lines
(Eca109, Ec9706 and TE-1) (Figure 2C). These data sug-
gested that alteration of miR-124 might be a frequent
event in human esophageal cancer and has a pivotal role
in the tumorigenesis of esophageal cancer.
MiR-124 overexpression suppresses proliferation and
induces apoptosis of esophageal cancer cells
As miR-124 expression consistently decreases in esopha-
geal cancer tissues and cells, we sought to compensate for
its loss through exogenous transfection with miR-124
mimic into Eca109 and TE-1 cells. Upon transfection,
the intracellular levels of miR-124 were about 130-fold
and 90-foud higher in Eca109 and TE-1, respectively
(Figure 3A). Then, we explored the effects of miR-124
on the proliferation and apoptosis of these two cell
lines. As expected, ectopic expression of miR-124 led
to significant decrease in cell proliferation in both
esophageal cell lines (Figure 3B). Cells transfected with
miR-124 showed a significant decrease in the percentage
of cells in S phase (P < 0.01) and an increase in the per-
centage of cells in G1 phase (P < 0.01) (Figure 3C). Fur-
thermore, we explored the biological role of miR-124 on
the apoptosis of Eca109 and TE-1 cells using the PE
Annexin V staining assays. Cells undergoing early apop-
tosis bind only to annexin V, and cells binding both are ei-
ther in the late stages of apoptosis or already dead. As
shown in Figure 3D, ectopic miR-124 expression increased
proportions of annexin V –positive only cells compared to
scramble control group (P < 0.05) (Figure 3D), suggesting
miR-124 can efficiently induce apoptosis of esophageal
cancer cells.
Ectopic expression of miR-124 significantly impairs the
migratory capacity of esophageal cancer cells
Considering the important role of metastasis in the tumor
progression, we sought to further evaluate the effects of
miR-124 on the migratory and invasive capacity of Eca109
and TE-1 cells using Matrigel migration and invasion as-
says, respectively. For both experiments, cells were main-
tained in serum-free medium during the course of assays
to avoid any augmented migratory behavior that could be
affected by cell proliferation. Firstly, we found that re-
expression of miR-124 in TE-1 and Eca109 cells resulted
in a significant reduction in cell migration compared with
the control groups (P < 0.01) (Figure 4A). For invasive as-
says, the transwell chambers were coated with Matrigel that
mimics the extracellular matrix. As shown in Figure 4B,
Figure 2 Expression level of miR-124 in esophageal cancer tissues and cell lines. (A) The expression of miR-124 in 67 pairs of esophageal cancer tissues
and compared normal tissues was detected using TaqMan quantitative RT-PCR. Data are shown as log10 of relative ratio change of esophageal cancer
tissues relative to normal tissues; (B) Statistical analysis of relative miR-124 expression levels in esophageal cancer tissues and compared normal tissues;
(C) Using quantitative RT-PCR analysis, the expression of miR-124 in four esophageal cancer cell lines (Eca109, Ec9706 and TE-1) was analyzed relative
to normal esophageal cell line Het-1A. The expression of miR-124 were normalized to small nuclear RNA U6. **P < 0.01.
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passing through the chambers coated with Matrigel, which
means miR-124 significantly suppressed the invasive cap-
acity of TE-1 and Eca109 cells. Taken together, these results
indicated a significant role of miR-124 on repressing cell
motility and invasiveness of esophageal cancer cells in vitro.
STAT3 is involved in miR-124-mediated tumor
suppression
The results mentioned above strongly suggested the
tumor suppressor role of miR-124 in esophageal cancer,
while the role of STAT3 in miR-124-mediated suppres-
sive effects remains unknown. To further explore
whether miR-124-mediated growth inhibition in esopha-
geal cancer cells via the direct targeting of STAT3, we
adopted a “rescue” methodology. We generated a new
construct containing the full ORF of STAT3 gene
(pcDNA3.1-STAT3). As expected, the expression of
STAT3 was rescued when pcDNA3.1-STAT3 was trans-
fected into Eca109 cells that had been treated with miR-
124 mimic before (Figure 5A). In agreement with the re-
stored expression of STAT3 protein, increased cellproliferation (Figure 5B) was observed upon transfection
with pcDNA3.1-STAT3. Moreover, restored expression
of STAT3 also partially abolished the suppressive effects
of miR-124 on cell invasive capacity (Figure 5C). These
data established the participation of STAT3 in miR-124
pathway, i.e. the tumor suppressor role of miR-124 in
esophageal cancer might be typically a consequence of
decreased STAT3 expression.
MiR-124 inhibited the growth of Eca-109-engrafted
tumors
Our above findings indicated that miR-124 was potential
therapeutic targets in esophageal cancer. To further ex-
plore the therapeutic effect of miR-124 on esophageal
tumorigenicity in vivo. 4 × 106 Eca-109 cells were inocu-
lated subcutaneously in posterior flanks of immunocom-
promised “nude” mice. When tumors reached 100 mm3,
synthetic miR-124 or scramble mimic were injected into
the tumors. After six consecutive injections, we found
that injection with miR-124 inhibited the growth of Eca-
109-engrafted tumors with respect to scramble mimic-
treated tumors (Figure 6A, 6B). Otherwise, in agreement
Figure 3 MiR-124 suppresses esophageal cancer cell growth. (A) RT-PCR was performed to detect the expression of miR-124 in esophageal cancer cell
lines (Eca109 and TE-1) after treatment with miR-124 mimic (normalized to U6); (B) CCK-8 assays were performed to analyze the effect of miR-124 on cell
proliferation of Eca109 and TE-1 cells; (C, D) The influences of miR-124 on cell apoptosis and cell cycle progression were analyzed using
fluorescence-activated cell sorting (FACS); *P < 0.05; **P < 0.01.
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treated by miR-124 mimic was significantly lower than
scramble mimic-injected tumors (Figure 6C). To further
identify the role of miR-124 in the suppressive role, we
explored the expression of miR-124 and STAT3 in the
engrafted tumors. As expected, the expression of miR-
124 was significantly up-regulated, while the expression
of STAT3 was suppressed in engrafted tumors treated
with miR-124 mimic. These data indicated that intro-
duction of miR-124 remarkably inhibited the tumorigen-
icity of Eca-109 cells in the nude mouse xenograft
model, providing a novel method for esophageal cancer
therapy.
Discussion
Although several molecular alterations were identified,
esophageal cancers still represent a major challenge of
interdisciplinary oncology [24]. Among of which, STAT3
signaling pathway is particular an important one. STAT3always play a critical role in oncogenic signaling in the
carcinogenesis and progression of several cancers. In
normal cells, STAT3 expression and activity is under
tight control to ensure physiological cell proliferation,
survival, differentiation and motility. For esophageal can-
cer, constitutively activated STAT3 expression was found
in both esophageal squamous cell carcinomas (ESCC)
and Barrett’s adenocarcinomas (BAC) [25]. While, the
mechanisms involved in its activation remain to be fur-
ther identified. Excepts for the potential STAT3 gene
amplification on chromosome 17q21, a region frequently
amplified in esophageal adenocarcinomas [26],
inflammation-associated STAT3 activation is also con-
ceivable, at least in vivo [27]. In this paper, we found an-
other way mediated the overexpression of STAT3. The
prediction program identified the putative binding site
of miR-124 in the 3’UTR of STAT3, and we found that
overexpression of miR-124 significantly suppressed the
expression of STAT3 and its downstream genes in
Figure 4 MiR-124 inhibits cell migration and invasion. (A, B) The effects of miR-124 on cell migration and invasion were detected using transwell chamber
assays. Panel A showed the results on migration; Panel B showed the results on invasion. The chambers have been coated with Matrigel, which functions
as the extracellular cell matrix. MiR-124 inhibited cells invasion through the membrane. *P< 0.05; **P< 0.01.
Figure 5 MiR-124 suppresses tumor progression through targeting STAT3 in esophageal cancer cells. (A) Upon transfection with STAT3
construct, we rescued the expression of STAT3 in Eca109 cells; (B) CCK-8 assays were used to detect to explore the effects of miR-124/STAT3
interaction on cell proliferation; (C) Transwell assays were performed to detect the effects on cell invasion of Eca109 cells treated as described
in B. *P < 0.05; **P < 0.01. Data are presented as means ± SD. Statistical analysis was carried out using ANOVA.
Cheng et al. BMC Cancer  (2015) 15:306 Page 8 of 11
Figure 6 MiR-124 inhibits esophageal cancer growth in vivo. (A) Graphic representing tumor volumes at the end of the experiment for mice treated with
miR-124 mimic or scramble mimic. Four mice per group; (B) Tumor volume averages between scramble and miR-124 mimic treated mice groups at the
indicated days during the experiment; (C) Tumor weight averages between scramble and miR-124 mimic treated mice groups at the end
of the experiment (28 days); (D) Quantitative RT-PCR analysis showed the relative expression of miR-124 in injected tumor tissues (normalized to U6);
(E) Immunochemistry analysis showed the expression of STAT3 in injected tumor tissues. **P < 0.01.
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in vivo.
Recently, the role of miRNAs in the initiation and main-
tenance of human diseases has been widely investigated.
Considered to be important components of gene regulators,
miRNAs play a critical role in the regulation of gene ex-
pression and are emerging as novel biomarkers of the dis-
eases [28]. The role of miR-124 has been reported in a
variety of cancers, while, so far, few studies addressed miR-
124 expression and function in esophageal cancers. Hence,
the present study comprehensively addressed these ques-
tions in esophageal tissues specimens and cell lines. We
found that the majority of esophageal carcinomas showed
under-expression of miR-124 (67%). This is consistent with
Chen et al., whose work suggested that dysregulation of
miR-124 presents borderline longer overall survival and
relapse-free survival in acute myeloid leukemia [29].
Otherwise, the expression of miR-124 was reported to
be attenuated in human breast cancer tissues, and is re-
versely correlated with histological grade of the cancer
[30]. Herein, we also found some negative relationshipbetween the expression of miR-124 and the clinical and
pathological features of esophageal cancer. Although no
statistical correlations were observed between miR-124 ex-
pression and gender, age, tumor size, TNM stages and me-
tastasis, low level of miR-124 was found to significantly
correlate with higher histological grade and tumor loca-
tion, suggesting that miR-124 might function as a tumor
suppressor in esophageal cancer and play a critical role in
the progression of esophageal carcinogenesis.
Next, we further explored the comprehensive biological
function of miR-124 on the malignant phenotype of
esophageal cancer cells. The expression of miR-124 in TE-1
and Eca109 cells were restored using a transient miRNA
mimic treatment protocol. As expected, over-expression of
miR-124 markedly inhibited cell proliferation, arrested cell
cycle progression and induced cell apoptosis of both cell
lines. Moreover, miR-124-transfected cells also showed a
dramatic decrease in cell migration and invasion. These re-
sults shown here demonstrate that miR-124 could suppress
the carcinogenesis of esophageal in vitro. These results are
consistent with Silber et al. reports. They found that miR-
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growth in vivo of medulloblastoma cells by targeting
cyclin-dependent kinase 6 (CDK6) [31]. In our in vivo
study, treatment of miR-124 also reduced tumor burden
in nude mice, suggesting that miR-124 inhibits the tumor
growth of esophageal cancer in vivo. Moreover, immuno-
hischemistry assays showed that in the xenografts of mice
the expression of STAT3 was significantly suppressed in
the miR-124-treated group, which is negatively correlated
with the expression of miR-124. These results further
identify miR-124 functions as a tumor suppressor in
esophageal cancer through, at least partially, targeting
STAT3 signaling pathway. As expected, restoring the ex-
pression of STAT3 in both esophageal cancer cell lines
partially abolished miR-124-mediated tumor suppression.
Although we did not explore the role of STAT3 in
esophageal cancer cells in this paper, it has been widely
performed by others. Timme et al. reported that STAT3
knockdown reduced cell proliferation and migration of
esophageal cancer cells OE33 [25]. A similar study found
that STAT3 overexpression affected the proliferation and
colony formation of Eca109 cells by altering Erk and Akt
activation. STAT3 regulated the migration and invasion
of Eca109 cells independent of Oct-1, while in conjunc-
tion with Oct-1, STAT3 inhibited apoptosis of Eca109
cells [10]. Based on the findings that inhibition of
STAT3 resulted in a near complete phenocopy of the
effects of miR-124, thus, we speculate that STAT3 is a
central for the suppressive actions of miR-124 in
esophageal cancer, which means down-regulation of
miR-124 in esophageal cancer cells may contribute to
the increased expression of STAT3 and in turn facilitate
the esophageal carcinogenesis.Conclusion
Taken together, our results establish a functional link
between miR-124 and STAT3 expression in esophageal
cancer, demonstrating that STAT3 is directly repressed
by miR-124, which subsequently inhibits its down-
stream signaling pathway. Restoring miR-124 function
could represent an alternative approach to reduce
therapeutically STAT3 expression, thereby attenuating
aggressive tumor properties. Collectively, this finding
not only helps us understand the molecular mechanism
of esophageal carcinogenesis, but also gives us a strong
rationale to further investigate miR-124 as a potential
biomarker and therapeutic target for esophageal cancer.
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